Anebulo Pharmaceuticals, Inc. (ANEB) — Institutional Holders, Q4 2025
19 institutional investment managers reported a ANEB position on SEC Form 13F-HR for the quarter ended December 31, 2025, with a combined reported value of $91.6M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
ANEB in Q4 2025: what funds did
Funds that filed a 13F for both Q3 2025 and Q4 2025, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- VANGUARD GROUPAdded · +129,281 sh+$130.6K
- Rangeley CapitalAdded · +30,000 sh+$30.3K
- CITADEL ADVISORSNew · +24,239 sh+$24.5K
- UBS Group AGAdded · +2,114 sh+$2.1K
- Tower Research Capital (TRC)Added · +1,480 sh+$1.5K
Biggest sellers
- Ikarian CapitalTrimmed · -139,984 sh-$141.4K
- XTX Topco LtdSold out · -19,153 sh-$19.3K
- BOOTHBAY FUND MANAGEMENTSold out · -18,836 sh-$19.0K
- GEODE CAPITAL MANAGEMENTTrimmed · -13,348 sh-$13.5K
- RENAISSANCE TECHNOLOGIESTrimmed · -3,402 sh-$3.4K
ANEB 13F holders ranked 1–19 of 19
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q3 2025 |
|---|---|---|---|---|---|
| 1 | 22NW#1 · 15,467,300 sh | 15,467,300 | $84.8M | — | 0.0% |
| 2 | Nantahala Capital Management#2 · 3,036,325 sh | 3,036,325 | $3.1M | — | 0.0% |
| 3 | MANGROVE PARTNERS IM#3 · 2,525,252 sh | 2,525,252 | $2.6M | — | 0.0% |
| 4 | VANGUARD GROUP#4 · 435,821 sh | 435,821 | $440.2K | 0.00% | +42.2% |
| 5 | MORGAN STANLEY#5 · 399,404 sh | 399,404 | $403.4K | — | 0.0% |
| 6 | GEODE CAPITAL MANAGEMENT#6 · 160,760 sh | 160,760 | $162.5K | — | -7.7% |
| 7 | Rangeley Capital#7 · 50,000 sh | 50,000 | $50.5K | — | +150.0% |
| 8 | RENAISSANCE TECHNOLOGIES#8 · 25,098 sh | 25,098 | $25.3K | — | -11.9% |
| 9 | CITADEL ADVISORS#9 · 24,239 sh | 24,239 | $24.5K | — | New |
| 10 | BlackRock#10 · 23,790 sh | 23,790 | $24.0K | — | -1.1% |
| 11 | NORTHERN#11 · 21,994 sh | 21,994 | $22.2K | — | -9.8% |
| 12 | Ikarian Capital#12 · 17,736 sh | 17,736 | $17.9K | — | -88.8% |
| 13 | STATE STREET#13 · 12,768 sh | 12,768 | $12.9K | — | 0.0% |
| 14 | Tower Research Capital (TRC)#14 · 3,230 sh | 3,230 | $3.3K | — | +84.6% |
| 15 | UBS Group AG#15 · 2,334 sh | 2,334 | $2.4K | — | +960.9% |
| 16 | JPMORGAN CHASE#16 · 2,253 sh | 2,253 | $2.3K | — | -47.3% |
| 17 | BANK OF AMERICA#17 · 382 sh | 382 | $386.00 | — | -57.1% |
| 18 | ROYAL BANK OF CANADA#18 · 30 sh | 30 | $0.00 | — | New |
| 19 | FNY Investment Advisers#19 · 100 sh | 100 | $0.00 | — | +5.3% |
Funds that sold out of ANEB in Q4 2025 (4)
Held ANEB at the end of Q3 2025 and filed a Q4 2025 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q3 2025 |
|---|---|---|
| XTX Topco Ltd19,153 sh | 19,153 | $47.9K |
| BOOTHBAY FUND MANAGEMENT18,836 sh | 18,836 | $47.1K |
| BARCLAYS PLC399 sh | 399 | $998.00 |
| CITIGROUP6 sh | 6 | $15.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q4 2025. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q3 2025 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.